Multiomics analysis reveals sustained immune dysregulation in pediatric MIS-C patients compared to healthy controls.
This study utilized a multiomics approach to analyze plasma and peripheral immune cells from 13 acute MIS-C patients, 18 recovered MIS-C follow-ups, and 15 healthy pediatric controls. The investigation aimed to characterize the immune landscape during the acute phase and during recovery, extending up to 18 months post-onset. No specific medications were administered as part of the intervention, serving instead to observe natural disease progression and immune resolution.
Results indicated persistent immune activation in the MIS-C cohort. Circulating pro-inflammatory cytokines, including IL-8, IL-6, IL-1, IL-1{beta}, and TNF-{beta}, remained elevated up to three months after MIS-C onset. Similarly, circulating TH2-type cytokines such as IL-4, IL-5, and IL-13 showed sustained elevation during the same period. Furthermore, 75% (12 of 16) of the identified SARS-CoV-2 TCRs demonstrated cross-reactivity with autoantigens. Autoantibodies were elevated across 13 gene targets involving self-antigen peptides, and autoreactive TCR expansions persisted over time, correlating with cytokines involved in allergic inflammation.
Safety and tolerability data were not reported in this observational study. A key limitation is that few details regarding the underlying disease pathology have been resolved. Consequently, while findings point to a mechanism of sustained autoimmunity, the evidence is observational and does not establish causality. The study did not report adverse events, discontinuations, or specific funding conflicts. Clinicians should interpret these immunological markers as indicators of prolonged immune dysregulation in MIS-C recovery, noting that the data lacks statistical precision and detailed pathological context.